Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBraveheart Inv Regulatory News (BRH)

Share Price Information for Braveheart Inv (BRH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.50
Bid: 6.00
Ask: 7.00
Change: 0.00 (0.00%)
Spread: 1.00 (16.667%)
Open: 6.50
High: 6.50
Low: 6.50
Prev. Close: 6.50
BRH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Investment in mLED Limited

2 Jul 2010 07:00

RNS Number : 6835O
Braveheart Investment Group plc
02 July 2010
 



2 July 2010

Braveheart Investment Group plc

("Braveheart" or the "Group")

 

Investment in mLED limited

 

Braveheart (AIM: BRH), the technology commercialisation and investment management company, today announces an investment into mLED Limited ("mLED" or "the Company"), a spin-out from the University of Strathclyde ("Strathclyde" or "the University"). The £150,000 funding package comprises funds from Braveheart's Strathclyde Innovation Fund and its Alpha Fund, as well as from Scottish Enterprise's Seed Fund.

 

mLED is a newly formed company, which has developed its technology at the University's Institute of Photonics ("IoP"). The IoP is recognised as a world leading institute in the development and supply of micro light emitting diodes ("microLEDs").

 

microLEDs are devices made up of thousands of tiny emitters producing light in a compact, integrated package. Unlike other micro-display technologies, microLEDs do not require a plethora of external components, such as optics and switching matrices, to modulate the light pattern, thereby making them more compact and efficient and ideal for miniature applications.

 

The IoP and its work has generated enquiries from academic and industrial bodies on availability of microLED devices for a range of applications including optogenetic studies. Optogenetics is a relatively new body of research in neuroscience and is being used in order to gain an understanding of how the brain processes information in order to precisely identify circuitry implicated in neurodegenerative disorders. It is anticipated that optogenetic tools and the resultant findings will revolutionise medical science and could impact on future treatments for conditions such as Alzheimer's, Parkinson's, depression and chronic pain. The Company is planning on initially addressing the neurotechnology market which, is forecast to grow from US$3.6 billion in 2008 to US$8.8 billion in 2012/13. 

 

Other applicable market sectors include micro-displays, wireless communications, microscopy, pico projection, general lighting, printing and photolithography.

 

Commenting on the investment, Geoffrey Thomson, Chief Executive of Braveheart said; "We are delighted to support another spin-out from the University of Strathclyde. mLED has some very promising technology and we look forward to supporting them through the next exciting stage of their development."

 

Dr Jim Bonar, CEO of mLED, said "mLED is extremely pleased to have gained exclusive rights to world-leading microLED technology. This funding will enable mLED to develop product capabilities in a range of markets, including evolving life science markets such as neuroscience and also to supply mLED development kits, thus, offering developers the ability to integrate microLED array technology into their own innovative applications."

 

For further information please visit www.braveheartinvestmentgroup.co.ukor www.mled-ltd.com or contact:

 

Braveheart Investment Group plc

Tavistock Communications (for Braveheart)

Geoffrey Thomson, Chief Executive

Simon Hudson / James Midmer

Tel: 01738 587555

Tel: 020 7920 3150

gthomson@braveheart-ventures.co.uk

shudson@tavistock.co.uk

 

MLED Ltd

 

Dr Jim Bonar

 

Tel: 07970062014

 

jim.bonar@mled-ltd.com

 

 

Notes to Editors

 

Braveheart

Braveheart Investment Group is a technology commercialisation and investment management company based in Perth, Scotland. It was founded in 1997 by a small group of investors in order to encourage and syndicate investments in privately held companies that offered opportunities for significant growth. Thirteen years on, Braveheart is a public company with offices in Perth, London and Yorkshire, and a demonstrable track record in early stage technology investing as well as an established client base of high net worth individuals. Service offerings include bespoke EIS portfolios, fund management, investment facilitation and management services.

 

Investments are made in young, emerging, unlisted companies where there is potential for significant growth through successful commercialisation of IP. Through close relationships with a number of leading universities and innovation centres Braveheart has access to a wide variety of emerging commercial opportunities at early stages. There are currently around 30 companies in Braveheart's diverse portfolio and it has completed over 80 deals in its 13 year history.

 

The Strathclyde Innovation Fund ("SIF" or "the Fund")

An agreement to create the Strathclyde Innovation Fund was announced in 2007 by Braveheart and the University of Strathclyde. SIF has the exclusive right of first refusal to fund all commercial investment opportunities that arise in respect of intellectual property emanating from the University of Strathclyde. The fund is unique in its structure and is the first of its kind in a UK higher education institution. A first closing of the fund was achieved in September 2008, with initial commitments totalling £4.5 million from investors including Braveheart, the University of Strathclyde and Strathclyde alumni. This also included Scottish Enterprise's Scottish Co-investment Fund, which will co-invest alongside the SIF by committing a specific allocation for use by SIF. SIF will operate for an initial period of eight years, extendable to 10 with the agreement of the partners in the fund.

 

Braveheart Investment Group's operating subsidiary Braveheart Ventures also acts as Fund Manager of SIF. Under the terms of the partnership, 25 per cent of the Fund Manager's performance bonus is paid back to the University, providing it with further direct benefit from those opportunities which succeed in generating returns. SIF also makes a small contribution to the running costs of a department that sponsors a successful investment application.

 

mLED is SIF's third investment.

 

The Alpha EIS Fund ("the Fund")

Established in December 2005, the £2.5 million Fund was set up as a tax efficient vehicle to invest in early-stage, university spin-out companies, rich in intellectual property, with potential for significant growth, through the commercialisation of their IP.

 

The Fund is managed by Braveheart Ventures, and participants and co-investors include Scottish Enterprise's Scottish Co-investment Fund and Braveheart's own clients. The Fund committed to deliver a minimum of ten EIS qualifying investments, sourced through the Group's unique framework of strong formal relationships with Scottish universities and business parks.

 

mLEd is Alpha's 11th investment and to date it has invested approximately £1.5 million.

 

Scottish Enterprise

Scottish Enterprise is Scotland's main enterprise, innovation and investment agency and is focused on supporting business growth and developing a competitive business environment. Working in partnership with industry, academia and the public sector, SE aims to play its part in delivering the Scottish Government's new economic strategy to increase productivity in Scotland by helping businesses grow, encouraging greater innovation and creating the right conditions for companies to access property, markets and finance.

 

Scottish Enterprise has a joined up investment approach which offers risk capital investment for Scottish businesses at various stages of growth. The Scottish Seed Fund provides equity and, in some cases, loan investments from £20,000 to £100,000 to early-stage businesses that meet the criteria and are keen to grow. The Scottish Co-investment Fund is a £72 million equity investment fund established by Scottish Enterprise, and partly funded by the European Regional Development Fund, to invest from £100,000 to £1 million in company finance deals of up to £2 million. The Scottish Venture Fund was set up by Scottish Enterprise in conjunction with the Scottish Government to invest £500,000 to £2 million in company finance deals of between £2 million and £10 million. 

 

Further information can be found at www.scottish-enterprise.com

 

Institute of Photonics

The Institute of Photonics, established in 1996, is a commercially-oriented research unit, part of the University of Strathclyde. The Institute's key objective is to bridge the gap between academic research and industrial applications and development in the area of photonics.

 

The Institute's research interests include semiconductor materials and devices, practical, all solid state lasers, micro-LED arrays and a wide range of applications particularly in biophotonics.

 

The Institute of Photonics is based in Strathclyde's Glasgow city centre campus

 

Further information can be found at www.photonics.ac.uk/welcome.html 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBUGDRRXGBGGB
Date   Source Headline
29th Apr 20242:07 pmRNSHolding(s) in Company
29th Apr 20241:42 pmRNSBlock admission six monthly return
10th Apr 20247:00 amRNSHolding(s) in Company
27th Mar 202412:03 pmRNSHolding(s) in Company
6th Mar 20247:00 amRNSAcquisition of further interest in Autins Group
4th Mar 202411:48 amRNSInvestment update – Paraytec Limited
4th Mar 20247:00 amRNSCompletion of sale of Phasefocus
9th Jan 202412:00 pmRNSHolding(s) in Company
22nd Dec 20231:30 pmRNSHolding(s) in Company
22nd Dec 20237:00 amRNSPortfolio update - Proposed sale of Phasefocus
15th Dec 202311:41 amRNSInvestment update - Paraytec Limited
15th Dec 202310:16 amRNSReplacement: Half-year Report
14th Dec 20237:00 amRNSHalf-year Report
29th Nov 20237:00 amRNSInvestment update - Paraytec Limited
14th Nov 20239:02 amRNSHolding(s) in Company
17th Oct 20237:00 amRNSInvestment update – Paraytec Limited
10th Oct 202311:15 amRNSHolding(s) in Company
8th Sep 20237:00 amRNSInvestment update – Kirkstall Limited
8th Sep 20237:00 amRNSBlock admission six monthly return
21st Aug 20237:00 amRNSFurther investment in Phasefocus Holdings Limited
28th Jul 20232:25 pmRNSInvestment update on Paraytec Limited
28th Jul 202311:54 amRNSResult of AGM
5th Jul 20237:00 amRNSPosting of annual report and notice of AGM
4th Jul 20237:00 amRNSHolding(s) in Company
3rd Jul 20237:00 amRNSFinal Results for the year ended 31 March 2023
31st May 20237:00 amRNSInvestment update – Phasefocus Holdings Limited
3rd May 20237:00 amRNSUpdate on investments
24th Apr 202310:49 amRNSHolding(s) in Company
27th Mar 20237:00 amRNSGrant of options
13th Mar 20239:34 amRNSHolding(s) in Company
9th Mar 20237:00 amRNSBlock admission six monthly return
10th Feb 20231:26 pmRNSHolding(s) in Company
30th Jan 20234:37 pmRNSHolding(s) in Company
16th Jan 20237:00 amRNSDirector/PDMR Shareholding
10th Jan 20237:00 amRNSOperational update
22nd Dec 20229:14 amRNSHolding(s) in Company
19th Dec 20229:25 amRNSDirector/PDMR Shareholding
19th Dec 20229:11 amRNSAcquisition of interest in Image Scan Holdings plc
13th Dec 20224:37 pmRNSHolding(s) in Company
15th Nov 20223:09 pmRNSHolding(s) in Company
7th Nov 20227:00 amRNSDirector/PDMR Shareholding
28th Oct 20227:00 amRNSHalf-year Report
21st Oct 202210:33 amRNSHolding(s) in Company
20th Oct 20221:59 pmRNSAcquisition of further interest in Autins
5th Oct 20223:15 pmRNSHolding(s) in Company
5th Oct 202212:28 pmRNSAcquisition of further interest in Aukett Swanke
30th Sep 20225:00 pmRNSTotal Voting Rights
20th Sep 20227:00 amRNSPlacing and subscription to raise £750,000
9th Sep 20227:00 amRNSBlock admission six monthly return
6th Sep 20227:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.